医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Personalis and the Garvan Institute Announce Commercial Partnership for Whole Human Genome Sequencing, Analysis and Interpretation

2014年10月20日 PM09:00
このエントリーをはてなブックマークに追加


 

MENLO PARK, Calif. & SYDNEY

Personalis, Inc., a leading genomics-based clinical research and diagnostics global service provider based in the USA, and the Garvan Institute of Medical Research in Sydney, Australia, today announced plans to form a commercial partnership designed to bring together best-in-class solutions for high-quality, large-scale human whole genome sequencing, analysis and interpretation for researchers and clinicians, worldwide.

The Garvan Institute of Medical Research, one of Australia’s leading medical research institutions, created the first purpose-built facility in its country for undertaking large-scale clinical research projects and ultimately clinical-grade genome sequencing for diagnostic purposes.

“We are excited to enter into a partnership that will allow researchers and clinicians worldwide to leverage Garvan’s sophisticated sequencing expertise and large-scale sequencing platforms, and for all parties involved to benefit from Personalis’ sophisticated pipeline, analysis experience, and core infrastructure capabilities that have been expertly honed through the analysis of thousands of human genomes,” said John West, Chief Executive Officer at Personalis. “Whole human genome sequencing analysis can be daunting, complex and time-consuming. This agreement will accelerate the pace of scientific research and clinical diagnosis by facilitating rapid, comprehensive and accurate whole genome sequencing combined with high-quality analysis and easy-to-interpret reports for large projects involving human data.”

Associate Professor Marcel Dinger, Head of the Kinghorn Centre for Clinical Genomics at the Garvan Institute, added: “The expertise at Personalis in analyzing, annotating and interpreting human genome sequencing data and in designing human genome research studies for clinical diagnostics is first-class, and we are delighted to combine our world-class facilities in a way that will benefit researchers and clinicians worldwide.”

Leadership from both organizations are present to discuss their individual and combined solutions at the 2014 American Society of Human Genetics Annual Meeting, which is now underway in San Diego. For more information about the meeting visit http://www.ashg.org/2014meeting/.

About Personalis, Inc.

Personalis, Inc. provides researchers and clinicians advanced genomics sequencing and interpretation services for inherited genetic disease and cancer. Our ACE (Accuracy and Content Enhanced) Technology supplements a standard exome or genome, substantially increasing its medically-relevant coverage and accuracy. Personalis builds on this enhanced sequencing foundation with innovative algorithms and proprietary databases for alignment, variant calling, annotation, and analysis. Through this comprehensive approach, we provide genomic data and interpretation of the highest accuracy. Personalis’ ACE Clinical Exome™ Test has several major features that are not addressed by standard exome sequencing platforms: a high level of gene finishing, structural variant detection, and inclusion of non-exonic biomedical content. The ACE Clinical Exome Test has been specifically designed to enhance diagnostic yield for clinical care.

For more information about Personalis, Inc., please visit www.personalis.com.

About the Garvan Institute for Medical Research

The Garvan Institute of Medical Research was founded in 1963 and is now one of Australia’s largest medical research institutions with over 600 scientists, students and support staff. Garvan’s main research areas are: Cancer, Diabetes & Metabolism, Immunology and Inflammation, Osteoporosis and Bone Biology, and Neuroscience. Garvan’s mission is to make significant contributions to medical science that will change the directions of science and medicine and have major impacts on human health. The outcome of Garvan’s discoveries is the development of better methods of diagnosis, treatment, and ultimately, prevention of disease.

In 2012, Garvan established Australia’s first purpose-built facility for undertaking large-scale genome sequencing projects. The Kinghorn Centre for Clinical Genomics (KCCG) researchers undertake collaborative projects and genome-based studies to improve genome interpretation, with the ultimate aim of advancing the use of genomic information in patient care. KCCG is seeking accreditation that would ultimately allow clinicians to sequence genomes for diagnostic and therapeutic purposes.

Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20141020005399/en/

CONTACT

Media Contact for Personalis
Maurissa Messier, 760-659-6700
pr@personalis.com
or
Media
Contact for Garvan Institute

Alison Heather
Science
Communications Manager
T: +61 (0) 2 9295 8128; M: +61 (0) 434 071
326
a.heather@garvan.org.au

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Intercell USA Changes Name to Valneva USA, Inc. and Expands Commercial Presence
  • ADC Therapeutics präsentiert Zwischenergebnisse aus Phase-I-Studie zu neuartigem Antikörper-Wirkstoff-Konjugat ADCT-402
  • Bertin与Zymo Research宣布达成新的合作
  • ベルタンとザイモリサーチが新しい連携を発表
  • The First China (Chongqing) Selenium Enrichment Industry Development Conference, Organized by the Chongqing Jiangjin Agriculture Commission, Was Held in Jiangjin